| 11.12 0.445 (4.17%) | 09-15 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 14.5 | 1-year : | 16.35 |
| Resists | First : | 12.41 | Second : | 14 |
| Pivot price | 12.46  |
|||
| Supports | First : | 9.85 | Second : | 8.19 |
| MAs | MA(5) : | 11.16 |
MA(20) : | 12.54 |
| MA(100) : | 9.72 |
MA(250) : | 7.13 |
|
| MACD | MACD : | -0.1 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 22.3 |
D(3) : | 15 |
| RSI | RSI(14): 43.3 |
|||
| 52-week | High : | 14 | Low : | 4.34 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ CADL ] has closed above bottom band by 16.8%. Bollinger Bands are 69.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 11.15 - 11.21 | 11.21 - 11.26 |
| Low: | 10.29 - 10.35 | 10.35 - 10.4 |
| Close: | 11.02 - 11.12 | 11.12 - 11.21 |
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.
Sun, 13 Sep 2026
CADL Slides As Form 144 Filing Flags Insider Selling Risk - timothysykes.com
Sat, 12 Sep 2026
CADL Slides As Candel Therapeutics Posts Wider Q2 Loss - StocksToTrade
Fri, 11 Sep 2026
Candel Therapeutics CEO Tak sells $3.16m in CADL stock - Investing.com
Thu, 10 Sep 2026
CADL: BLA submission for aglatimogen in prostate cancer is planned by year-end, with key data updates ahead - TradingView
Thu, 10 Sep 2026
CADL 8-K Filings - Candel Therapeutics, Inc. SEC 8-K - Stock Titan
Thu, 10 Sep 2026
A drug-development expert with 30 years’ experience joins Candel’s board - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 77 (M) |
| Shares Float | 60 (M) |
| Held by Insiders | 14.8 (%) |
| Held by Institutions | 67 (%) |
| Shares Short | 12,460 (K) |
| Shares Short P.Month | 12,960 (K) |
| EPS | -1.48 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.65 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -28.7 % |
| Return on Equity (ttm) | -81.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.94 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -56 (M) |
| Levered Free Cash Flow | -36 (M) |
| PE Ratio | -7.57 |
| PEG Ratio | 0 |
| Price to Book value | 6.69 |
| Price to Sales | 0 |
| Price to Cash Flow | -15.19 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|